The expansion of bioprocessing facilities is a key driver of growth in the Protein A resin . Bioprocessing facilities, including contract manufacturing organizations (CMOs) and biopharmaceutical companies, are continually increasing their production capacities to meet the rising demand for biologics, particularly monoclonal antibodies (mAbs).
As the prevalence of chronic and autoimmune diseases grows, there is an escalating need for effective and targeted therapies, leading to an increased focus on biopharmaceuticals. Protein A resins play a crucial role in the downstream processing of mAbs, facilitating their purification and isolation from complex biological mixtures. The expansion of bioprocessing facilities allows manufacturers to upscale their production and, consequently, drives the demand for Protein A resins.
According to Coherent Market Insights, the global protein A resin market is estimated to account for US$ 511.7 Mn in terms of value in 2020 and is expected to reach US$ 907.3 Mn by the end of 2027.
Moreover, the globalization of the biopharmaceutical industry has led to a geographically dispersed manufacturing landscape. Biopharmaceutical companies are establishing production facilities in various regions to cater to local and regional s, necessitating the installation of advanced purification technologies like Protein A resins in these facilities.
Additionally, the increasing adoption of contract manufacturing services by emerging biotechnology companies further contributes to growth. CMOs play a vital role in providing manufacturing expertise and infrastructure to small and mid-sized biotech firms, and Protein A resins are an integral part of their purification processes.
Furthermore, as the biopharmaceutical industry continues to evolve, newer applications of Protein A resins are being explored beyond mAb purification. The expansion of bioprocessing facilities allows for greater research and development opportunities, leading to the discovery of novel applications in diagnostics, regenerative medicine, and industrial biotechnology.
In conclusion, the expansion of bioprocessing facilities, driven by the growing demand for biologics and the globalization of the biopharmaceutical industry, is a significant factor influencing the Protein A resin . As manufacturers seek to increase their production capacities and explore new therapeutic avenues, the demand for Protein A resins is expected to experience continued growth.
Comments
0 comment